LLY
NYSEHealthcareEli Lilly & Co
Last 60 sessions
2026-11-12 21:03 UTC
Indicator panel
EMA 21
$1,347.89
EMA 50
$1,274.84
EMA 200
$1,135.85
RSI 14
68.0
70 overbought · 30 oversold
RVOL
0.80x
vs 20-session average
ADX 14
38.3
DI+ 35.3 · DI- 14.7
MACD
56.87
Signal 52.85
52w high
$1,460.00
52w low
$850.51
Price performance
1 week
+4.6%
1 month
+18.1%
3 months
+20.9%
6 months
+41.8%
1 year
+39.5%
Levels and risk
Support
$1,119.00
Resistance
$1,449.68
Volatility (ann.)
32.6%
Max drawdown (6m)
-12.9%
Support and resistance come from the pivot bands of the last 60 sessions. They are descriptive levels, not price targets.
Data still to connect
- Company fundamentals (revenue, EPS, market cap) need a licensed fundamentals provider — not connected.
- Earnings calendar, company news and SEC filings need news/SEC data providers — not connected.
Technicals computed from 251 daily bars (USD, delayed). Research and education only — not personalised investment advice.
Five analysts consensus
78/ 100
SableTrend Analyst
EMA 21 / 50 / 200
Bullish88- Price above EMA 21 ($1347.89).
- EMA 21 above EMA 50 — short-term structure intact.
- EMA 50 above EMA 200 — primary uptrend.
- EMA 21 rising over the last ten sessions.
VeraMomentum Analyst
RSI 14
Bullish91- RSI 68.0 — strong momentum without exhaustion.
- RSI rising over the last week.
RhodesVolume Analyst
Relative Volume
Neutral50- Volume 0.80x its 20-session average.
VesperStrength Analyst
ADX 14 · DI+ / DI-
Bullish88- ADX 38.3 with DI+ 35.3 above DI- 14.7 — strong uptrend.
CyrusMaster Expert
MACD 12 / 26 / 9
Bullish74- MACD above its signal line, histogram cooling at 4.02.
- MACD line above zero — medium-term momentum positive.
Read it as a desk
Sable reads structure, Vera reads momentum, Rhodes reads participation, Vesper reads trend strength and Cyrus ties the four into one MACD-led verdict. When they disagree, the score stays near the middle on purpose — the desk does not force a call.
Compare against the full scan